Oyster Point Pharma Inc. (NASDAQ: OYST) has announced that the US FDA has approved TYRVAYA nasal spray 0.03mg for dry eye disease symptoms and signs treatment.
TRYVAYA Nasal Spray only licensed for dry eye disease treatment
Currently, TRYVAYA Nasal Spray is the first and only nasal spray licensed for the treatment of dry eye conditions. As a treatment for dry eye conditions, TYRVAYA Nasal Spray is thought to bind to cholinergic receptors and stimulate the trigeminal parasympathetic pathway, resulting in increased basal tear film production. Oyster Point is a commercial-stage biopharmaceutical firm focused on developing and commercializing first-in-class medicines for ocular illnesses.
TYRVAYA Nasal Spray is a selective cholinergic agonist that is sprayed twice daily into each nostril as a liquid nasal spray to stimulate basal tear production. The use of a nasal spray in treating dry eye conditions is a novel technique to avoid putting medicine on an already inflamed ocular surface. Furthermore, nasal administration could enable certain patients who have trouble self-administering topical eye drops to self-administer their dry eye condition treatment.
TYRVAYA approval is a major milestone for Oyster Point
The company’s CEO and President Jefferey Nau said, “The approval of TYRVAYA Nasal Spray marks a milestone for patients and eye care professionals by providing a new drug treatment option for the signs and symptoms of dry eye disease with a differentiated route of administration that is believed to leverage a nerve pathway that can be accessed within the nose.”
Nau added, “In any therapeutic area, it’s always an exciting moment when you follow the science and develop a truly innovative pharmaceutical treatment option for patients that addresses an important unmet medical need. In conjunction with the FDA, it has been an honor to work alongside my colleagues at Oyster Point to bring TYRVAYA Nasal Spray to the dry eye disease community. We look forward to making TYRVAYA Nasal Spray available to eye care professionals and their patients.”
